| Document |
Document Title |
|
JP2864885B2 |
|
|
JPH11502419A |
Novel derivatives of LSD having the formula wherein R1 is an alkyl, cycloalkyl or aryl group having 1 to 10 carbon atoms, preferably an alkyl group having 1 carbon atom; R2 is a bond or wherein R3 is alkyl, cycloalkyl or aryl group havin...
|
|
JPH1087662A |
To obtain a new compound, used in immunoassay for detecting lysergic acid diethylamide(LSD) and its metabolite and useful for preparing an antigenic reagent, an antibody reagent or a tracer reagent. This compound is represented by formul...
|
|
JPH1072372A |
To prepare a medicine capable of reducing body fat storage and mitigating insulin resistance, hyperinsulinism, hyperglycemia and type II diabetes by resetting the daily rhythm of prolactin in a human, etc., at that of a thin and healthy ...
|
|
JP2655706B2 |
Compounds of the formula I wherein R1 represents a hydrogen atom or a methyl group, either R2 and R3 represent hydrogen atoms or together represent a chemical bond, R4 represents a hydrogen atom or a C1-C4 alkyl group, R5 represents a C1...
|
|
JP2653835B2 |
This invention provides (8 beta )-N-cycloalkyl-1-alkyl-6-(substituted)ergoline-8-carboxamide
s of the formula wherein: R<1> is C1-C4 alkyl; R<2> is allyl or C1-C4 straight chain alkyl; R<3> is hydrogen or C1-C4 straight chain alkyl; R<4>...
|
|
JPH09508351A |
The invention relates to N-alkyl peptide chelate formers, their metal complexes with radionuclides, processes for their production and radio-pharmaceutical compositions containing these compounds. The invention also relates to radio-phar...
|
|
JP2618375B2 |
Terguride and its physiologically compatible salts can be used for the treatment of geriatric deficiencies, e.g., in doses of 0.1-5.0 mg/day.
|
|
JP2540019B2 |
PURPOSE: To obtain a pharmaceutical composition especially used for the whole body transdermal administration of a pharmacologically active material. CONSTITUTION: This pharmaceutical composition is the one for the whole body transdermal...
|
|
JPH08208479A |
PURPOSE: To obtain a nonnarcotic analgesic containing a specific crabbine alkaloid derivative, having substance P receptor-antagonistic action, and safely usable for patients suffering from chronic rheumatism, neuralgia, osteoporosis, en...
|
|
JPH085879B2 |
The invention relates to a novel process for the halogenation in 2-position of ergot alkaloids. The process is characterized by that as a halogenating agent a system consisting of dimethylsulfoxide, a trialkylhalosilane or triarylhalosil...
|
|
JPH07121944B2 |
Processes for the preparation of esters of N1-methyl-10α-methoxylumilysergol are described, in which lysergol esters are subjected to N-methylation and subsequently to photochemical reaction with methanol/H2SO4. The esters of N,- methyl...
|
|
JPH0791290B2 |
Novel ergoline derivatives, substituted in the 2-position, of the formula (I) wherein C8---C9 and C9---C10 each independently is a CC-single or a C=C-double bond, but not together a cumulated double bond, and the substituent in the 8-pos...
|
|
JPH0788380B2 |
|
|
JPH0780877B2 |
|
|
JPH0747587B2 |
A method of preparing lysergol derivatives, particularly 10α-methoxy lumilysergol, 1-methyl-10a-methoxy-lumilysergol and C8 esters of 1-methyl-10a-methoxy-lumilysergol, is provided characterised in that lysergol esters are subjected to ...
|
|
JPH0745498B2 |
Ergoline derivatives of general formula I wherein either R1 represents a hydrogen atom or a methoxy group and R2 represents a hydrogen atom or R1 and R2 taken together represent a chemical bond, and R3 represents a hydrogen atom, an unsu...
|
|
JPH07118270A |
PURPOSE: To provide a new compound having a remarkably strong vasodepressor activity, reduced in toxicity, excellent in safety and useful as a therapeutic agent for hypertension, etc. CONSTITUTION: A compound is represented by formula I ...
|
|
JPH0723375B2 |
Ergoline Esters I (R1=H or CH3; R2=C1-C4 hydrocarbon; R3=H or OCH3; R4=H or halogen; R5=C1-C4 alkyl) and their pharmaceutically acceptable salts are active in the central nervous system level. A process for their preparation is also desc...
|
|
JPH0723376B2 |
Compounds of the formula wherein R is primary or secondary C1-C8 alkyl, C2-C4 alkenyl-CH2, C3-C8 cycloalkyl or C3-C6 cycloalkyl-substituted C1-C5 primary or secondary alkyl, the total number of carbon atoms in R not to exceed 8; R<1> is ...
|
|
JPH0717640B2 |
Novel 12- and 13-substituted ergoline derivatives are suitable, e.g., as psychopharmaceuticals and for hypertension therapy.
|
|
JPH0717639B2 |
Ergoline derivatives of the formula Iwherein R1=H, CH3; R2=H, halogen, CH3, CN, C1-C4 alkylthio or phenylthio; R3=C1-C4 hydrocarbon; R4=H, OCH3; R5=H and R6=-CH=CH-CONHR7 or R5 + R6= =CH-CONHR7; R7= 2-thiazolyl, 3-pyridazinyl, 1,3,4-thia...
|
|
JPH06511480A |
A process for the long term modification and regulation of lipid and glucose metabolism-generally to reduce obesity, insulin resistance, and hyperinsulinemia or hyperglycemia, or both (these being the hallmarks of noninsulin dependent, o...
|
|
JPH0699429B2 |
NEW MATERIAL:The compound of formula I (R is univalent N-containing 5-membered ring residue having the free bond at the N atom, e.g. imidazol-1-yl, 2-oxo- oxazolidin-3-yl, etc.). EXAMPLE:1-(6-Methylergolin-8beta-ylmethyl)imidazole. USE:P...
|
|
JPH06321971A |
PURPOSE: To provide a new compound having excellent lasting release performance useful for treatment of Raynaud's disease, scleroderma, acrocyanosis or the like. CONSTITUTION: This compound of formula [Alk is cathion derived from natural...
|
|
JPH0670048B2 |
The present invention provides a process for decyanating a pergolide intermediate with an alkali metal hydroxide in an alcoholic solvent.
|
|
JPH0670050B2 |
Novel 12- and 13-bromoergoine derivatives are suitable as medicines for treating psychic disorders of the depressive array of symptoms and also as intermediates.
|
|
JPH0670051B2 |
The disclosure relates to 1,2-substituted ergoline derivatives of general Formula I (I) wherein X is an oxygen or sulfur atom, R1 is a lower alkyl group, R2 is halogen, acyl, a saturated or unsaturated lower alkyl group which can optiona...
|
|
JPH0669951B2 |
Method of blocking 5HT2 without effect on alpha receptors with 1-loweralkyl-6-straight chain alkyl-8β-hydroxycyclo- alkyloxycarbonylergolines of the formulawherein R is primary or secondary C1-C8 alkyl, CH2C2-C4 alkenyl, C3-C8 cycloalky...
|
|
JPH0669950B2 |
A method of inducing neuron protective activity in warm-blooded animals comprising administering to warm-blooded animals an amount sufficient to induce protective activity of at least one compound of the formula I wherein R and R2 are in...
|
|
JPH0670049B2 |
The present invention provides a process for preparingwherein R' is C3-Ce alkyl, -CH2C2-C4 alkenyl, propargyl, C3-C8 cycloalkyl or C1-C6 alkyl substituted C3-C8 cycloalkyl; which comprises: reacting a compound of Formula (II):with a subs...
|
|
JPH0670052B2 |
8 alpha -Acylaminoergoline useful in the treatment of psychotic disorders and Parkinson's disease.
|
|
JPH0667835B2 |
The present invention provides a pharmaceutical composition for the transdermal systemic administration of a pharmacologically active agent characterised in that it contains tizanidine as active agent in a reservoir comprising a hydrophi...
|
|
JPH0667935B2 |
|
|
JPH0667936B2 |
A process for preparing an N-methyl derivative of ergoline of formula: in which R1 denotes a carboxy or alkoxycarbonyl group in which the alkyl portion contains 1 to 4 carbon atoms, R2 denotes a hydrogen atom or a methoxy group and R3 de...
|
|
JPH0667938B2 |
Novel 1-alkyl ergolinylthiourea derivatives of the general formula wherein R1 is C1-6 alkyl, R2 and R3 are C1-4 alkyl, R4 is hydrogen or C1-4 alkyl and C9--C10 is a single bond or a double bond, and the acid addition salts thereof, with ...
|
|
JPH0667937B2 |
A process for preparing an N-methyl derivative of methyl dihydrolysergate and methyl methoxylumilysergate, of formula: in which R1 denotes a hydrogen atom or a methoxy group, which comprises reacting a methylating agent with a compound o...
|
|
JPH0667934B2 |
Process for the preparation of 1-methyllysergol and of 10 alpha -methoxy- 1-methyllumilysergol by the action of a base on a solution of lysergol or of a 10 alpha -methoxylumilysergol in a polar aprotic solvent, followed by a methylating ...
|
|
JPH0655739B2 |
Compounds of the formula I (I) wherein R1 is hydrogen or C1-4alkyl, R2 is hydrogen, chlorine, bromine or methyl, R3 is C1-5alkyl or C3-5alkenyl and R4 is C3-7alkyl; C3-7cycloalkyl; adamantyl; or optionally substituted phenyl, having valu...
|
|
JPH06206878A |
PURPOSE: To provide a new compound useful for treating agents of hypertension, migraine, anxiety, depressions, obesity or the like. CONSTITUTION: The compound of the formula I, e.g. 9,10-dihydro-N-(2'- propynyl)-6-methylergoline-8β-carb...
|
|
JPH0631232B2 |
1. Process for the preparation of 8 alpha-substituted 6-methyl-10 alpha-H-ergolines of the general formula : see diagramm : EP0032684,P4,F1 in which R**1 is NH-CO-NR2 , CO-NH-NR2 , CONR2 or CH2 OR (wherein R in each case represents hydro...
|
|
JPH0687743A |
PURPOSE: To provide a tranquilizer contg. terguride or its pharmaceutically acceptable salt, as an active ingredient. CONSTITUTION: The terguride is capable of acting only on an abnormally active cerebral cortex-intermediate cerebral per...
|
|
JPH0680639A |
PURPOSE: To obtain piperidones and tetrahydropyridones useful as intermediates for pharmaceutically active compounds by reacting an appropriately substituted enamine with a particular acryloyl derivative. CONSTITUTION: The compound of fo...
|
|
JPH06501031A |
PCT No. PCT/DE92/00569 Sec. 371 Date Mar. 12, 1993 Sec. 102(e) Date Mar. 12, 1993 PCT Filed Jul. 9, 1992 PCT Pub. No. WO93/01185 PCT Pub. Date Jan. 21, 1993.2,14-Disubstituted ergolines of formula I he meaning named in the application, a...
|
|
JPH064626B2 |
|
|
JPH05507722A |
PCT No. PCT/DE92/00088 Sec. 371 Date Oct. 7, 1992 Sec. 102(e) Date Oct. 7, 1992 PCT Filed Feb. 6, 1992 PCT Pub. No. WO92/13857 PCT Pub. Date Aug. 20, 1992.A process for the production of ergoline derivatives of general formula I is descr...
|
|
JPH0556349B2 |
1. A process for the preparation of 2-bromo-8-ergolinyl compounds of the formula I see diagramm : EP0141387,P4,F4 wherein R**8 is NH2 , NH-CONE2-t , CONH2 , see diagramm : EP0141387,P4,F5 and see diagramm : EP0141387,P5,F1 wherein R**1 i...
|
|
JPH05504358A |
New substituted urea compounds of formula I, or a pharmaceutically acceptable salt thereof: (* CHEMICAL STRUCTURE *) I wherein A is (* CHEMICAL STRUCTURE *) wherein R3 is an oxadiazol, substituted with C1-8-alkyl, C2-8-alkenyl, C2-8 alky...
|
|
JPH0529227B2 |
The invention relates to a novel process for the preparation of partially new 2-halonicergoline derivatives of the formula (I), (I) wherein X stands for chlorine, bromine or iodine atom, as well as their acid addition salts. The process ...
|
|
JPH0524918B2 |
Compounds I (R = H, CH3; R1 = H, halogen, CH3, phenylthio, C1 - C4 alkylthio; R2 = H, CH3O and R3 = H or R2 + R3 = chemical bond; R4 = C1 - C4 hydrocarbon; R5, R6, R8, R9 independently = H, C1 - C4 alkyl or R5, R8 independently = H, C1 -...
|
